Non-small-cell lung cancer patients harboring TP53/KRAS co-mutation could benefit from a PD-L1 inhibitor Supplementary Figure 1
Chenyue Zhang, Kai Wang, Jiamao Lin & Haiyong Wang
Non-small-cell lung cancer patients harboring TP53/KRAS co-mutation could benefit from a PD-L1 inhibitor Supplementary figure
This data repository is not currently reporting usage information. For information on how your repository can submit usage information, please see
our documentation.